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ABSTRACT 
 
BACKGROUND: Diabetic retinopathy (DR) is a blinding disease of increasing prevalence, 
caused by a complex interplay of genetic and environmental factors. Here we describe the 
patient recruitment methodology, case and control definitions, and clinical characteristics 
of a study sample to be used for genome-wide association (GWAS) analysis to detect 
genetic risk variants of DR.  
METHODS: 1669 participants with either type 1 (T1) or type 2 (T2) diabetes mellitus (DM) 
aged 18 to 95 years were recruited in Australian hospital clinics. Individuals with T2DM 
had disease duration of at least 5 years, and were taking oral hypoglycemic medication, 
and/or insulin therapy. Participants underwent ophthalmic examination. Medical history 
and biochemistry results were collected. Venous blood was obtained for genetic analysis. 
RESULTS: 683 diabetic cases (178 T1DM and 505 T2DM participants) with sight-
threatening DR, defined as severe non-proliferative DR (NPDR), proliferative DR (PDR) or 
diabetic macular edema (DME) were included in this analysis. 812 individuals with DM but 
no DR or minimal NPDR were recruited as controls (191 with T1DM and 621 with T2DM). 
The presence of sight-threatening DR was significantly correlated with DM duration, 
hypertension, nephropathy, neuropathy, HbA1C and BMI. DME was associated with T2DM 
(p<0.001), whereas PDR was associated with T1DM (p<0.001).  
CONCLUSIONS: Adoption of a case-control study design involving extremes of the DR 
phenotype makes this a suitable cohort, for a well-powered GWAS to detect genetic risk 
variants for DR.  
 
Keywords: diabetic retinopathy, diabetic macular edema, genome wide association study.
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INTRODUCTION 
 
Diabetic retinopathy (DR) is the leading cause of blindness in working age adults1. The 
Australian National Diabetes Information Audit and Benchmark exercise (ANDIAB) from 
2009 reports that diabetic Australians with access to large diabetes centres for screening 
and treatment have a prevalence of DR of 29%, and a rate of blindness approaching 1%2. 
The diabetic complication rates of those living in remote Australia with limited access to 
healthcare are much greater, with a rate of vision threatening retinopathy between 7 and 
11% 3-5.  
 
Landmark trials over the last 30 years have been crucial in substantiating an association 
between the development and progression of DR and risk factors including diabetes 
mellitus (DM) duration, glycemic control, hypertension and hyperlipidemia6-8. The focus of 
recent research on DR susceptibility has moved to the contribution of genetic susceptibility 
to DR development and severity. The Diabetes Control and Complications Trial (DCCT) 
was the first large-scale trial to investigate and determine a significant correlation between 
patients and their first-degree relatives in relation to the presence and severity of DR, 
independent of glycemic control 9. Significant familial aggregation of DR severity across a 
range of ethnic groups was subsequently demonstrated, with the degree of heritability 
dependent on ethnicity10. The heritable component of sight-threatening DR has been 
reported to be between 25% and 50%10,11.  
 
Genome-wide association studies (GWAS) have been conducted to investigate the genetic 
contribution to DR susceptibility, but to date, results have not been reproducible across 
studies and studies have lacked appropriate statistical power to detect variants of even 
modest effect size12,13. A number of functional candidate genes for DR susceptibility have 
Archived at Flinders University: dspace.flinders.edu.au
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been studied, including aldose reductase (ALR), angiotensin converting enzyme (ACE), 
vascular endothelial growth factor (VEGF) and nitric oxide synthase (NOS)14. The efficacy 
of inhibiting the VEGF pathway in the treatment of diabetic macula edema (DME) 
demonstrates the clinical relevance of research aimed at elucidating the genetic risk 
factors, and the associated molecular pathways involved in the pathogenesis of sight-
threatening DR. Such improved understanding is required to facilitate the development of 
personalized approaches, and novel therapeutic strategies to reduce the burden of 
diabetes associated visual morbidity. 
 
The sample presented in this paper is a current representation of Australian type 1 (T1) 
and type 2 (T2) diabetes patients from an era in which the importance of glycemic control 
and systemic vascular risk factors have been well understood. The target population 
includes individuals with DM affected by potentially sight-threatening complications of DM, 
as well as individuals who have DM without retinopathy. The eventual outcome of this 
study is to investigate the influence of genetics on the development and severity of DR, 
specifically using GWAS methodology to identify candidate single-nucleotide 
polymorphisms (SNPs). An understanding of the molecular pathogenesis of DR would 
have significant implications for screening strategies and the development of novel 
therapies. The present report describes the recruitment methodology, case control 
definitions, and the clinical characteristics of the sample to be studied. 
 
METHODS 
 
Ethics approval: 
In South Australia, ethics approval was obtained from the Southern Adelaide Health 
Service Flinders University Clinical Research Ethics Committee (Flinders Medical Centre 
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and Repatriation General Hospital), and the Human Research Ethics Committees (HREC) 
of the Royal Adelaide Hospital and Queen Elizabeth Hospital. In New South Wales and 
Victoria, the HREC of Southeastern Sydney and Illawara Northern Hospital Network 
(Sydney Eye Hospital), and the HREC of Melbourne Health (Royal Melbourne Hospital) 
approved this study. The ACT Health HREC approved this study in the Australian Capital 
Territory. The study adhered to the tenets of the Declaration of Helsinki.  
 
Participant recruitment and consent: 
In 2007 recruitment of participants began from three tertiary hospitals in metropolitan 
Adelaide, South Australia: The Flinders Medical Centre, the Royal Adelaide Hospital and 
the Queen Elizabeth Hospital. The project was expanded to the Royal Melbourne Hospital 
(Melbourne, Victoria) in 2009, the Sydney Eye Hospital (Sydney, New South Wales) in 
2010, and the Repatriation General Hospital (Adelaide, South Australia), and The 
Canberra Hospital (Canberra, Australian Capital Territory) in 2011. Moorfields Eye 
Hospital (National Institute for Health Research (NIHR) Biomedical Research Centre at 
Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, 
London, United Kingdom) has become the first international recruitment centre for this 
study. Recruitment from this site, along with participants from ongoing recruitment 
throughout Australia will be used for replication analysis following GWAS. 
 
Ophthalmology, endocrinology and renal clinics of these hospitals were used to identify 
and recruit participants with diabetes meeting eligibility criteria. A combination of 
sequential recruitment, and opportunistic recruitment with a bias towards patients with 
more severe diabetic complications occurred. Written, informed consent was obtained 
from all participants following explanation of the nature and possible consequences of the 
study. 
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Case and control definitions 
Eligibility criteria for this study required that participants were at least 18 years of age and 
had either T1DM of any duration, or T2DM of at least 5 years duration. All participants 
must be taking oral hypoglycemic medication, or be on insulin therapy, or both. Individuals 
with diet-controlled DM were excluded.  
 
Cases included those with sight threatening DR, meeting at least 1 of the following criteria: 
1. Worst ever retinopathy grading of severe non-proliferative diabetic retinopathy 
(NPDR) or proliferative diabetic retinopathy (PDR) in at least 1 eye; 
2. The presence or history of DME in at least 1 eye. 
 
Controls were defined as those whose retinopathy grading had never been worse than 
minimal NPDR, and who had no current or previous history of DME in either eye. Those 
with mild or moderate NPDR were recruited for the longer term study of issues such as 
progression, but excluded from specific analyses comparing cases and controls for the 
purpose of the planned GWAS. 
 
Clinical data collection: 
Full ophthalmic examination was performed according to existing site specific clinical 
practice. Acuity was assessed with either Snellen or logMAR charts, and recorded in the 
database as Snellen equivalent.  Examination of the anterior segment included specific 
assessment of any lens opacity, and also the presence or absence of rubeosis.  
Intraocular pressure was measured with either a Goldmann tonometer, or an iCare 
tonometer (iCare Finland Oy, Revenio Group Corporation, Helsinki, Finland). Retinal 
examination was performed with slit lamp biomicroscopy. Retinopathy status was clinically 
Archived at Flinders University: dspace.flinders.edu.au
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graded according to the Early Treatment Diabetic Retinopathy Study criteria with the 
following stages: no DR, minimal NPDR, mild NPDR, moderate NPDR, severe NPDR, 
PDR, or DME15. Worst ever retinopathy status for the worse eye was used in the analyses. 
Participants were classified as having DME irrespective of their DR grading if they were 
found to have DME in either one or both eyes. Those who had received laser treatment or 
intravitreal injections for sight-threatening DR were graded according to their retinopathy 
status prior to treatment (ie their worst ever grading). Participants with active disease were 
documented with color photography, fundus ﬂuorescein angiography (FFA), and optical 
coherence tomography (OCT) of the macula as clinically indicated at the discretion of the 
treating clinician, but the clinical grading as determined at the time of slit lamp 
biomicroscopy was used for classification. Ophthalmologists were contacted to obtain 
ophthalmic examination data of participants recruited who attended private ophthalmology 
clinics. 
 
For individuals in whom FFA was clinically indicated, a digital mydriatic retinal camera was 
used to obtain retinal photographs. Prior to photography, pupils were further dilated with 
phenylephrine hydrochloride 2.5%. Macular OCT, including high definition macular scans, 
was performed for all patients with DME using a Cirrus HD-OCT (Carl Zeiss Meditec, 
California, USA). Patients who had a history of previous laser treatment but with currently 
inactive disease were not subjected to photography or OCT. 
 
A detailed questionnaire was administered to collect relevant information regarding social, 
demographic and medical history. Information collected included sex, age, ethnicity and 
lifestyle factors (cigarette smoking and alcohol history). Medical history data included DM 
type and duration, family history of DM, co-existing risk factors (systemic hypertension, 
hypercholesterolemia), history of vascular disease (ischemic heart disease (IHD), 
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cerebrovascular accident (CVA) or transient ischemic attack (TIA), peripheral vascular 
disease (PVD)), and history of diabetic complications (peripheral neuropathy, diabetic 
nephropathy and details of renal transplant or dialysis). Ophthalmic history was completed 
by the treating ophthalmologist and included details of past cataract surgery, age related 
macular degeneration (ARMD), glaucoma, retinal detachment, vitreous hemorrhage, 
rubeosis/iris neovascularisation and past treatment for DR (focal laser, macular grid laser, 
pan retinal photocoagulation (PRP), intravitreal injections, and vitrectomy). The year of 
development of sight-threatening DR was also documented.  
 
Height, weight and blood pressure measurements were taken at the time of recruitment. 
Individuals were classiﬁed as having hypertension if they were on pharmacologic 
treatment for hypertension, or they had a systolic or diastolic blood pressure reading 
greater than or equal to 140mmHg or 90 mm Hg respectively. 
 
Results of the participants’ previous blood tests were accessed from the medical record 
where available. The most recent serum lipid profile results (total cholesterol, HDL 
cholesterol, LDL cholesterol and triglycerides) were recorded. Hypercholesterolemia was 
defined as a total cholesterol greater than or equal to 5.5mM, or current use of lipid-
lowering medication. Renal function tests (serum creatinine, urine albumin, and albumin-
creatinine ratio) were also obtained. The most recent renal function results available were 
used for analyses except for those who were on dialysis or who had received a renal 
transplant, in which case results immediately prior to the start of dialysis or transplantation 
were used. Nephropathy was deﬁned as the presence of microalbuminuria (30 – 300 
mg/d) or macroalbuminuria (> 300 mg/d). The mean of three HbA1c levels was used for 
each participant. The 3 most recent values immediately prior to recruitment were used, 
except in cases of sight-threatening DR where 3 HbA1c values in the year of onset of 
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sight-threatening DR development were taken. 
 
Collection of DNA and serum: 
A venous blood sample was obtained from each participant by a trained venipuncturist. 
Two 9ml Vacuette EDTA tubes of venous blood were collected and stored at 4 degrees 
Celsius. DNA was extracted from the blood samples using the QiaAmp Blood Maxi Kit 
(Qiagen, Valencia, California). An 8ml Vacuette serum tube was also collected from a 
subset of approximately half the participants when the proximity of the recruitment site 
facilitated the timely processing of the sample. These serum tubes were centrifuged at 
2700g for 10 mins within 2 hours of collection. The serum was transferred to 1ml 
microfuge tubes, labeled and stored at -80 degrees Celsius for future analysis.  
 
Data analysis: 
All data recorded onto the data collection form were entered into a password protected 
Microsoft Office Access 2003 version 5.1 for Windows XP professional (Microsoft 
corporation, USA) electronic database. Statistical analysis was carried out using Statistical 
Package for Social Sciences (SPSS) version 20.0 for Mac OS X (IBM SPSS Statistics 
20.0, SPSS Inc., USA). Case and control groups were compared for differences in age 
and sex with a Mann-Whitney U test and a chi-squared test respectively. Data was 
characterized using basic descriptive statistics, and correlations between variables and 
phenotypes were assessed. Variables were analysed for differences between DM type 
using the Mann-Whitney U test and a chi-squared test. Analyses were considered for 
sight-threatening DR, PDR and DME subgroups, for T1DM and T2DM combined, and also 
stratified for type of DM. P values <0.05 were considered statistically significant. Odds 
ratios (OR) are presented with corresponding 95% confidence intervals. Power 
calculations were made with the online program Genetic Power Calculator16. 
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RESULTS 
 
Cases and controls 
A total of 1669 Caucasian individuals with DM were recruited for inclusion in GWAS 
analysis. Included were 683 cases with sight threatening DR and 812 diabetic controls as 
defined in methods. Of the cases, 215 patients with DME also had co-existing PDR or 
severe NPDR. A further 174 (10%) participants had DR that met neither sight threatening 
case or control criteria (ie. mild or moderate NPDR) for the purpose of the genome-wide 
association study. The sample comprised 407 (24%) T1DM and 1262 (76%) T2DM 
patients. Retinopathy gradings by type of DM are presented in table 1. 
 
Baseline characteristics of case and control groups were compared (Table 2). A Chi-
square test for independence (with Yates Continuity Correction) indicated significantly 
more male cases compared with controls for T2DM alone (χ2=6.9, p=0.008), and all DM 
irrespective of type (χ2=9.97, p=0.002). Age distribution was found to violate the 
assumption of normality for T1DM and T2DM patients alone and combined. A Mann-
Whitney U Test revealed no significant difference in age between case and control groups 
when pooling all diabetics (p=0.196). Analysis by DM type found that T1DM controls were 
significantly younger than cases (U=11957.5, p<0.001), but that T2DM controls were 
significantly older than cases (U=137741, p=0.001).  The baseline differences found 
between case and control groups will be accounted for in multivariate models for future 
analyses. 
 
Clinical variables 
Duration of DM ranged from 0-70 years with a mean duration of 18 years. The prevalence 
of co-morbidities was high, with 76% of participants having hypertension, 66% of 
participants having hyperlipidemia, and a mean body mass index (BMI) of 30.8 (range 
Archived at Flinders University: dspace.flinders.edu.au
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14.3-70.5; SD 6.6). Suboptimal diabetic control as determined by HbA1C was also 
common, with the sample having a mean HbA1C of 8.1% (range 2.2-15.3%; SD 1.6). 
Duration of diabetes, total cholesterol, systolic blood pressure, HbA1C and BMI were all 
unimodally distributed. 
 
Complications of DM (DR, nephropathy, neuropathy, IHD or stroke) were noted in 80% 
(1331 patients) of the sample. Of 741 patients who had urine albumin measurements 
available, 38% had nephropathy (26% with microalbuminuria, and 13% with 
macroalbuminuria), with 17 of these patients on dialysis and 5 having received renal 
transplants. 29% of patients had neuropathy, 24% had ischemic heart disease and 9% had 
a history of stroke. Clinical characteristics stratified by DM type are presented in table 3, 
with p-values comparing these variables between T1DM to T2DM participants.  
 
The correlation of clinical variables with type of DR was also examined (Table 4). Sight 
threatening DR, PDR and DME were assessed in separate models. Statistically significant 
(P < 0.05) correlations with one or more subgroups of DR were found for duration of 
diabetes, diabetes type, hypertension, nephropathy, neuropathy, HbA1C and BMI. 
Correlations were strongest for HbA1c, duration of diabetes, and nephropathy. 
Interestingly, PDR was correlated with T1DM (p<0.001), whereas DME was correlated 
with T2DM (p<0.001). 
 
Power 
Power for the planned GWAS was calculated using a specific type 1 error rate of 5x10-8 to 
allow for multiple hypothesis testing in a genome-wide association scan. Assuming a 
disease prevalence of any retinopathy of 0.3, this study has 94% power, to detect 
associated SNPs with an odds ratio of 1.3, if the minor allele frequency is at least 0.2.  
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DISCUSSION 
 
This manuscript describes the 683 cases and 812 controls for which clinical information 
and DNA have been collected. A GWAS to identify genes relating to the pathogenesis of 
DR in this study sample is currently underway.  
 
A number of candidate gene studies have investigated SNPs associated with DR. A meta-
analysis of previous candidate gene studies up to the year 2008 found that the biggest 
limitations in this field was varying case-control definitions and suboptimal power14. The 
largest candidate gene analysis of genes previously associated with DR, DN, T2DM and 
atherosclerotic cardiovascular disease has since been performed for 2691 participants 
with T2DM from the CARe consortium, and did not find substantial evidence for a DR 
gene17.  The most compelling results thus far have come from investigation of the Aldose 
reductase (AKR1B1) and VEGFA genes.  
 
Aldose reductase, involved in the polyol pathway, consumes NADPH while reducing 
glucose to sorbitol, and in turn contributes to microvascular damage through the 
exacerbation of intracellular oxidative stress18. The AKR1B1 gene has been investigated 
in a number of ethnic groups and DM types with varying findings. The z-2 allele of a short 
tandem repeat microsatellite marker has been associated with increased risk of DR in 
both T1DM and T2DM, whereas the z+2 allele has been shown to be protective against 
retinopathy in T1DM14. However, more recent multivariate analysis which accounted for 
confounding risk factors (including duration of DM and glycemic control), did not confirm 
these associations between the AKR1B1 gene and DR,19 indicating confounding factors 
contributing to the reported associations. No studies to date have specifically investigated 
the contribution of this gene to the development of DME. 
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VEGF has been shown to contribute to the development of diabetic microvascular 
complications including DR and DME through its role in angiogenesis, and the associated 
increase in vascular permeability20. A number of GWAS and candidate gene studies have 
reported associations of various VEGFA SNPs, though results have not been consistent 
between studies14. Two particular SNPs that combined represent nearly 50% of the VEGF 
variance have been assessed in a large case control study including 6920 T2DM 
participants, but neither appeared to be directly associated with the development of DR, 
DME or diabetic nephropathy (DN)21. The clinical benefit of intravitreal anti VEGF therapy 
for PDR and DME is now well substantiated22,23, however the complex genetic link 
between VEGF and diabetic microvascular complications may be indirect and requires 
further detailed investigation. 
 
Suboptimal power also remains problematic in recent GWAS, and as a result, genome 
wide significance has not been reached in any published study, nor has there been any 
consistency in genes identified between studies11,24-26. Studies so far have typically 
included samples from the entire range of DR severity, with case-control definitions 
comparing no DR with any DR24, or any DR with severe DR11,25. Given that the DR 
variants under investigation are likely to have small to moderate effect sizes, large sample 
sizes are required in order to reach statistical significance when using population 
sampling. However, there is good recent evidence to suggest that focusing on recruitment 
and analysis of phenotypic extremes results in systematically larger effect sizes than the 
overall population effect size27. This strategy has specifically been used in the discovery 
of rare variants, and is postulated to reduce the required sample size by as much as 
fourfold compared with sampling from the general population27. The case-control 
definitions adopted for the current study differ from GWAS performed to date by involving 
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analysis of phenotypic extremes. We have successfully employed this strategy using 
advanced glaucoma cases to detect two genome wide significant loci in a study of 650 
cases28. We expect results of the current study to be consistent with a sufficiently 
powered GWAS and the potential for detection of susceptibility loci for DR.  
 
Data from long-term prospective population based studies indicate that those with T2DM 
may be more susceptible to DME than those with T1DM, and that the difference in the 
incidence of DME between these groups becomes more pronounced as duration of DM 
increases29,30. Preliminary descriptive statistics of the present study sample are consistent 
with this finding, with double the prevalence of DME in T2DM compared with T1DM 
participants. The implication of this association during an era of rapidly increasing 
incidence of T2DM, on vision related quality of life and health care costs is particularly 
noteworthy. DME is the major vision threatening complication of DR and thus determining 
independent genetic risk factors for DME is imperative in achieving improved treatment 
strategies and outcomes.  
 
The complex integration between genetic susceptibility and environmental risk factors in 
the development of diabetic microvascular complications requires further investigation with 
large sample sizes and clear a priori case and control definitions in order to obtain 
meaningful results. Specific analysis of DME is warranted given the lack of current 
understanding of the genetic risk factors involved, and the associated visual morbidity of 
this type of DR. The size of the current sample has the capacity to detect genome wide 
significance. The potential outcome of this study is the identification of candidate genes 
involved in the development and progression of PDR and DME, to assist in the 
development of novel management strategies targeting this blinding disease of increasing 
prevalence.  
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TABLES: 
Table 1: Retinopathy gradings by diabetes type. Cases are defined as those with a worst ever 
retinopathy grading of sight threatening DR (severe NPDR, PDR and/or DME) in at least 1 eye. 
Controls are defined as those whose retinopathy grading has never been worse than minimal 
NPDR, and have had no history of DME. 
 
T1DM 
N (%) 
T2DM 
N (%) 
Combined 
N (%) 
N 407 1262 1669 
Cases 178 (43.7) 505 (40.0) 683 (40.9) 
Controls 191 (46.9) 621 (49.2) 812 (48.7) 
No DR 139 (34.2) 539 (42.7) 678 (40.6) 
Mild/Mod NPDR 60 (14.7) 265 (21.0) 325† (19.4) 
PDR 144 (35.4) 258 (20.4) 402 (24.1) 
DME 59 (14.5) 354 (28.1) 413 (24.7) 
Any DR 268 (65.8) 723 (57.3) 991 (59.4) 
T1DM indicates type 1 diabetes; T2DM, type 2 diabetes; DR, diabetic retinopathy; NPDR, non-proliferative 
diabetic retinopathy; PDR, proliferative diabetic retinopathy; DME, diabetic macular edema. 
†Co-existent DME was found in 151 of the 325 participants with mild or moderate NPDR. 
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Table 2: Features of cases and controls for all participants, and by diabetes type. Cases are 
defined as those with a worst ever retinopathy grading of sight threatening DR (severe NPDR, 
PDR and/or DME) in at least 1 eye. Controls are defined as those whose retinopathy grading has 
never been worse than minimal NPDR, and have had no history of DME. 
 
Cases 
(Sight threatening DR) 
Controls 
(No DR + minimal NPDR) 
 
Combined    
N 683 812  
Males (%) 401 (58.9) 410 (50.5) 
χ
2
(1, n=1494)=9.97 
p=0.002 
Mean age  SD 6015 6017 Mann-Whitney U=266539 
z=-1.29 
p=0.196 
Age range 21-91 18-95 
Median Age 61 63 
T1DM    
N 178 191  
Males (%) 104 (58.4) 94 (49.2) 
χ
2
(1, n=369)=2.8 
p=0.095 
Mean age  SD 4716 3915 Mann-Whitney U=11957.5 
z=-4.93 
p<0.001 
Age range 21-79 18-85 
Median age 46 37 
T2DM    
N 505 621  
Males (%) 297 (58.9) 316 (50.9) 
χ
2
(1, n=1125)=6.9 
p=0.008 
Mean age  SD 6411 6712 Mann-Whitney U=137741 
z=-3.51 
p=0.001 
Age range 33-91 23-95 
Median age 65 67 
DR indicates diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy. Sight-threatening DR is 
defined as severe NPDR or PDR and/or DME. 
 
Archived at Flinders University: dspace.flinders.edu.au
 22 
Table 3: Clinical characteristics of the cohort. The number of patients contributing data to each 
variable is given (N). Data is presented as mean +/- standard deviation or N (%). Where relevant, 
the range is also given. P-values are derived from Mann-Whitney U test for continuous variables 
and chi-squared test for categorical variables comparing TIDM to T2DM participants. 
Variable T1DM T2DM  
 N 
Mean  SD 
(Range) 
N 
Mean  SD 
(Range) 
 
P-value 
Total 407  1262   
Age at recruitment (years) 407 44  16 
(18-85) 
1262 66  12 
(23-95) 
 
<0.001 
Duration of diabetes (years) 406 23  13 
(0-70) 
1258 16  9 
(0-67) 
 
<0.001 
Serum creatinine (umol/L) 356 95  88 
(24-921) 
1005 114  116 
(32-1238) 
 
<0.001 
Total cholesterol (mmol/L) 351 4.7  1.1  
(1.1-10.4) 
994 4.3  1.1  
(1.3-10.9) 
 
<0.001 
Systolic Blood Pressure (mmHg) 361 131  18 
(90-197) 
1057 137  19 
(90-240) 
 
<0.001 
HbA1C (%) 394 8.4  1.6 
(4.6-14.4) 
1113 8.0  1.6 
(2.2-15.3) 
 
<0.001 
Body mass index 381 27.8  5.3 
(18.4-63) 
1148 31.8  6.7 
(14.3-70.5) 
 
<0.001 
 N N (%) N N (%) P-value 
Sex (male) 407 217 (53.3) 1262 695 (55.1) 0.749 
Family history of diabetes 362 200 (55.2) 1243 806 (64.8) <0.001 
Hypertension  406 201 (49.5) 1262 1072 (84.9) <0.001 
Hyperlipidaemia 407 193 (47.4) 1261 911 (72.2) <0.001 
Nephropathy 406 117 (28.8) 1259 426 (33.8) 0.041 
Dialysis 334 2 (0.6) 1083 15 (1.4) 0.269 
Renal transplant 334 1 (0.3) 1083 4 (0.4) 1.000 
Neuropathy 362 67 (18.5) 1258 412 (32.8) <0.001 
Peripheral vascular disease  362 39 (10.8) 1258 179 (14.2) 0.103 
Ischemic heart disease 362 41 (11.3) 1259 364 (28.9) <0.001 
Cerebrovascular accident 362 16 (4.4) 1258 131 (10.4) <0.001 
Smoking (current or ex-smoker) 407 204 (50.1) 1262 664 (52.6) 0.320 
T1DM indicates type 1 diabetes; T2DM, type 2 diabetes. 
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Table 4: Correlation of clinical variables with retinopathy grading. Pearson correlations are 
presented with corresponding p-values. Cases are defined as those with a worst ever retinopathy 
grading of sight threatening DR (severe NPDR, PDR and/or DME) in at least 1 eye.  
Variable 
 
Cases  
(Sight Threatening DR) 
PDR DME 
Duration of DM 0.37 (<0.001) 0.42 (<0.001) 0.30 (<0.001) 
T2DM -0.03 (0.26) -0.13 (<0.001) 0.11 (<0.001) 
Hypertension 0.12 (<0.001) 0.11 (<0.001) 0.14 (<0.001) 
Hyperlipidemia 0.02 (0.39) 0.02 (0.59) 0.05 (0.09) 
Nephropathy 0.23 (<0.001) 0.28 (<0.001) 0.19 (<0.001) 
Neuropathy 0.17 (<0.001) 0.19 (<0.001) 0.14 (<0.001) 
HbA1C 0.34 (<0.001) 0.36 (<0.001) 0.34 (<0.001) 
BMI 0.04 (0.17) 0.03 (0.37) 0.07 (0.02) 
DM indicates diabetes mellitus; T2DM, type 2 diabetes; DR, diabetic retinopathy; PDR, proliferative diabetic 
retinopathy; DME, diabetic macular edema. Sight-threatening DR is defined as severe NPDR or PDR and/or 
DME. 
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